Five Below (NASDAQ:FIVE – Get Free Report) had its price objective reduced by research analysts at Guggenheim from $140.00 to $125.00 in a research report issued to clients and investors on ...

Guggenheim initiated coverage of GH Research (GHRS) with a Buy rating and $32 price target The firm’s thesis on GH is based around the belief ...

Fintel reports that on March 13, 2025, Guggenheim initiated coverage of GH Research (NasdaqGM:GHRS) with a Buy recommendation ...

Absci (NASDAQ:ABSI – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at Guggenheim in a research ...

Guggenheim analyst Eddie Hickman initiated coverage of GH Research (GHRS) with a Buy rating and $32 price target Light Up your Portfolio with ...

Guggenheim Total Return Bond has used its atypical structure to great effect. Our research team assigns Silver ratings to strategies that they have a high conviction will outperform the relevant ...

Guggenheim expanded its risk-management capabilities ... also relies on the input of its portfolio construction and macro research teams. Walsh invests between USD 100,000 and USD 500,000 in ...

Guggenheim Investments is the global asset ... Our 235+ investment professionals perform rigorous research to understand market trends and identify undervalued opportunities in areas that are ...

Teams do not pay a fee for placement on Forbes Top Advisor rankings, which are independently determined by Shook Research. Source: Forbes.com (Awarded Jan 2025) Data Compiled By Shook Research LLC ...

Guggenheim initiated coverage of GH Research (GHRS) with a Buy rating and $32 price target The firm’s thesis on GH is based around the belief that rapid-acting psychedelics like 5-MeO-DMT have ...